Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730554) titled 'A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants' on July 23.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AbbVie
Condition:
Forehead Lines
Intervention:
Drug: AGN-151586
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 28, 2026
Target Sample Size: 80
To know more, visit https://clinicaltrials.gov/study/NCT07730554
Disclaimer: Curated by HT Sy...